Working… Menu
Trial record 99 of 150 for:    Ipratropium OR atrovent

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02173795
Recruitment Status : Completed
First Posted : June 25, 2014
Last Update Posted : July 14, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective of this study was to investigate patients acceptability / preference of Berodual® Respimat® inhaler as compared to the conventional Berodual® Metered Aerosol (MA) inhaler. Ease of handling and assembling the Respimat® inhaler at home under real life conditions was also evaluated.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Asthma Drug: Berodual® Respimat® Drug: Berodual® MA HFA Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 245 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Berodual® Respimat® Inhaler Versus Berodual® MA Using HFA (Hydrofluoroalkane) 134a as Propellant in Adult Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Conditions, an Open-label, Crossover Trial Over a 7-week Treatment Period With Each Formulation: ' A Study to Compare Patient Preference'
Study Start Date : October 2002
Actual Primary Completion Date : June 2003

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Berodual® Respimat® - Berodual® MA HFA

randomized sequence

  1. Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)
  2. Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)
Drug: Berodual® Respimat®
Drug: Berodual® MA HFA

Primary Outcome Measures :
  1. Patient's assessment of inhaler preference [ Time Frame: Day 98 ]
    patient preference questionnaire

Secondary Outcome Measures :
  1. Rating of inhaler satisfaction [ Time Frame: Day 49 and 98 ]
    patient satisfaction questionnaire

  2. Rating of willingness to continue using inhaler [ Time Frame: Day 98 ]
    patient preference questionnaire

  3. Post-dose PEFRpm (Peak expiratory flow rate) [ Time Frame: 30 minutes post-dose up to day 98 ]
  4. Retention of inhaler technique [ Time Frame: day 49 and 98 (after 7 weeks of treatment) ]
    proficiency questionnaire

  5. Use of rescue medication [ Time Frame: up to day 98 ]
  6. Daytime and night-time symptom scores [ Time Frame: up to day 98 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of chronic obstructive pulmonary disease, asthma, or mixed conditions for a minimum of 6 months
  • Male or female patients 18 years of age or older
  • Patients who use at least 2 puffs t.i.d. of Berodual® MA HFA on regular use or at least 4 weeks prior to study
  • Patients should be able to perform all study related tests including using a peak flow meter, to perform acceptable PEFR measurements, and should be able to maintain records (Patient Daily Diary Cards) during the study period as required in the protocol
  • All patients must sign and Informed Consent Form prior to participation in the trial, i.e., prior to the run-in period in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)

Exclusion Criteria:

  • Patients with significant disease other than chronic airways obstruction (CAO) will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  • Patients with a recent history (i.e., six months - or less) of myocardial infarction
  • Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalized for heart failure within the past three years, including patients with hypertrophic cardiomyopathy and tachyarrhythmia
  • Patients who regularly use oxygen therapy
  • Patients with known active tuberculosis
  • Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed
  • Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
  • Patients who have undergone thoracotomy with pulmonary resection. Patients with history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1
  • Patients with any upper or lower respiratory infection in the past six weeks prior to the screening visit (Visit 1) or during the run-in period
  • Patients hospitalized or having had visits to the emergency room in the past six weeks before run-in period
  • Patients who are currently in a pulmonary rehabilitation programme that will not be maintained throughout the duration of the study or who have completed a pulmonary rehabilitation programme in the six weeks prior to the screening visit (Visit 1)
  • Patients with known hypersensitivity to anticholinergic drugs or any other components of the trial medication including excipients
  • Patients medically treated for prostatic hyperplasia or bladder neck obstruction
  • Patients with known narrow-angle glaucoma or raised intra-ocular pressure
  • Patients who are being treated with beta-blocker medications Note: beta1-blocker eye medications for treatment of non-narrow angle glaucoma are allowed
  • Patients using oral corticosteroid medication at unstable dose (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day
  • Patients on inhaled or short-acting beta-adrenergics other than the study medication
  • Patients on inhaled or short-acting beta-anticholinergics other than the study medication
  • Patients taking monoamine oxidase inhibitors
  • Patients taking tricyclic antidepressants
  • Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for the previous three months (i.e., oral contraceptives, intrauterine inhalers, diaphragm or subdermal implants)
  • Patients with a history of and/or active significant alcohol or drug abuse
  • Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) prior to the screening visit (Visit 1)
  • Patients who have already been enrolled and randomised to a treatment group in this study

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02173795     History of Changes
Other Study ID Numbers: 215.1357
First Posted: June 25, 2014    Key Record Dates
Last Update Posted: July 14, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Fenoterol, ipratropium drug combination
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Cholinergic Agents